Prosecution Insights
Last updated: November 04, 2026
Application No. 18/377,942

RECRYSTALLIZATION METHOD FOR NMN PREPARATION

Non-Final OA §112
Filed
Oct 09, 2023
Priority
Aug 07, 2023 — CN 202310983672.8
Examiner
LEE, HOI YAN NMN
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Qingdao Restore Biotechnology Co. Ltd.
OA Round
2 (Non-Final)
38%
Grant Probability
At Risk
2-3
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
34 granted / 89 resolved
-21.8% vs TC avg
Strong +77% interview lift
Without
With
+76.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
48 currently pending
Career history
162
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
42.2%
+2.2% vs TC avg
§102
16.2%
-23.8% vs TC avg
§112
18.0%
-22.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 89 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action is responsive to Applicant’s Amendment and Remarks, filed June 8, 2026. The amendment, filed June 8, 2026, is acknowledged, wherein claims 1 and 3 – 4 are amended, claims 7 – 10 are canceled, and claims 11 – 13 are new. Claims 1 – 6 and 11 – 13 are pending in this application and are currently examined. Priority This application is a domestic application, filed October 9, 2023, which claims benefit of foreign priority document CN202310983672.8, field August 7, 2023. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application is pertinent only when interference arises. Withdrawn Objections The objection of claims 3 – 4 in the previous Office Action, dated March 31, 2026, is withdrawn in view of the amended claims 3 – 4. Withdrawn Rejections The rejection of claims 1 – 10 in the previous Office Action, dated March 31, 2026, under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention has been considered and is withdrawn in view of the amended claim 1. The rejection of claims 1 – 10 in the previous Office Action, dated March 31, 2026, under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention has been considered and is withdrawn in view of the amended claims 1 and 7 – 9. The rejection of claims 1 – 7 and 9 in the previous Office Action, dated March 31, 2026, under 35 U.S.C. 103 as being unpatentable over Akiyama in view of Fu et al., Fu et al. (US10214552B2, hereinafter ‘552B2), Suzuki, and Livingston et al. has been considered and is withdrawn in view of amended claim 1. The rejection of claim 8 in the previous Office Action, dated March 31, 2026, under 35 U.S.C. 103 as being unpatentable over Akiyama in view of Fu et al., Fu et al. (US10214552B2, hereinafter ‘552B2), Suzuki, and Livingston et al. as applied to claims 1 – 7 and 9 above, and further in view of Atsukawa et al. has been considered and is withdrawn in view of the canceled claim 8. The rejection of claim 10 in the previous Office Action, dated March 31, 2026, under 35 U.S.C. 103 as being unpatentable over Akiyama in view of Fu et al., Fu et al. (US10214552B2, hereinafter ‘552B2), Suzuki, and Livingston et al. as applied to claims 1 – 7 and 9 above, and further in view of Srinivasakannan has been considered and is withdrawn in view of the canceled claim 10. The following are maintained / modified / new grounds of rejection necessitated by Applicant’s Amendment and Remarks, filed June 8, 2026, wherein claims 1 and 3 – 4 are amended, claims 7 – 10 are canceled, and claims 11 – 13 are new. Previously cited references have been used to establish the maintained / modified / new grounds of rejection. New Claim Objections Claim 1 is objected to because of the following informalities: Claim 1, lines 3 – 42, recites “step 1.”, “step 2.”, “step 3.”, “step 4.”, “step 5.”, “step 6.”, step 7.”, “step 8.”, “step 9.”, “step 10.”, “step 11.”, and “step 12.”. According to MPEP § 608.01(m), each claim begins with a capital letter and ends with a period. Periods may not be used elsewhere in the claim except for abbreviation. See Fressola v. Manbeck, 36 USPQ2d 1211 (D.D.C. 1995). Appropriate correction is required. New Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 – 6 and 11 – 13 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding step 3 of claim 1, the claim recites an “activated phosphorylation reaction” comprising adding phosphoric acid to the buffer containing dissolved nicotinamide and ribose and stirring the mixture under appropriate temperature and pH conditions “to make reactions take place in the mixture”. However, it is unclear what reaction is required to occur during this step and what product is produced by the recited reaction. In particular, the claim does not specify whether the phosphoric acid reacts with nicotinamide, ribose, ribose-5-phosphate (R5P), or another component of the mixture, or whether ribose or R5P is converted to an intermediate required for subsequent NMN formation. The specification does not provide clarification, but merely repeats that phosphoric acid is added to the dissolved nicotinamide and ribose to make reactions take place in the mixture. Regarding step 4, the claim further recites adding “NMN synthetase” as a catalyst and states that the synthetase promotes “the reaction of nicotinamide and phosphoric acid to general NMN”. However, NAMPT, also known as nicotinamide phosphoribosyltransferase or NMN synthetase, is known in the art to catalyze formation of NMN from nicotinamide and phosphoribosyl pyrophosphate (PRPP), rather than from nicotinamide and phosphoric acid. PRPP, in turn, may be produced from R5P by phosphoribosyl pyrophosphate synthetase in an ATP-dependent reaction. Claim 1 does not recite PRPP or identify a reaction by which PRPP is produced, and it is unclear from the recited steps whether the ribose or R5P prepared or present in the preceding steps participates in the NMN-forming reaction. The specification also does not clarify how the recited nicotinamide and phosphoric acid react in the presence of NMN synthetase to generate NMN. Accordingly, in view of the inconsistency between the recited reaction and the known reaction catalyzed by NMN synthetase, and the absence of clarification in the specification as to the reaction occurring in step 3 and the substrates participating in the NMN-forming reaction of step 4, one of ordinary skill in the art would not be able to determine the metes and bounds of the reactions required by steps 3 – 4. Claims 2 – 6 and 11 – 13 depends from claim 1 and are, therefore indefinite. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1 – 6 and 11 – 13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The Applicant’s attention is drawn to re Wands, 8 USPQ2d 1400 (CAFC1988) at 1404 where the court set forth eight factors to consider where assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors: (1) The nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. The nature of the invention & The breadth of claims: The claimed invention is directed to a method for preparing NMN, including an activated phosphorylation reaction and an NMN synthetase-catalyzed reaction for generating NMN. In particular, step 3 requires adding phosphoric acid to a buffer containing dissolved nicotinamide and ribose and stirring the mixture under appropriate temperature and pH conditions to cause reactions to take place. Step 4 further requires adding an NMN synthetase as a catalyst, wherein the synthetase promotes the reaction of nicotinamide and phosphoric acid to generate NMN. Thus, the claimed method requires that these reactions be operative so that NMN is generated before the subsequent purification and recrystallization steps are performed. The enablement issue therefore concerns reactions that are quired by the claim itself and is not limited to an optional embodiment or an unclaimed aspect of the disclosure. The relative skill of those in the art: The relative skill of those in the art is high. The amount of direction or guidance presented & The presence or absence of working examples: The specification provides reaction temperature, pH ranges, reaction times, and an addition ratio of NMN synthetase to nicotinamide (para. [0022 – 0023]; para. [0057]; para. [0074]; para. [0091]; para. [00108]). However, the specification does not identify what reaction occurs during the “activated phosphorylation reaction” of step 3, what product or intermediate is produced, or how phosphoric acid, ribose, and R5P participate in that reaction. With respect to step 4, the specification merely states that MNM synthetase promotes the reaction of nicotinamide and phosphoric acid to generate NMN, without explaining the reaction pathway or identifying the ribose-containing substrate necessary for formation of NMN. The specification contains embodiments describing the claimed sequence of steps and provides generation conditions (para. [0041 – 00110]). However, the embodiments do not provide an operative working example demonstrating production of NMN through the recited reaction of nicotinamide and phosphoric acid in the presence of NMN synthetase. In particular, the specification does not provide experimental data, reaction yields, analytical characterization, or other results establishing that NMN is actually generated by the reaction recited in steps 3 and 4. Accordingly, the examples do not provide one of ordinary skill in the art with an operative demonstration of the claimed NMN-forming reaction. The state of prior art: Takahashi et al. (Journal of Biochemistry, 2010, Vol. 147, Issue 1, page 95 – 107, PTO-892) teach that nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the reaction of nicotinamide (NAM) and 5-phosphoribosyl-1-pyrophosphate (PRPP) to form nicotinamide mononucleotide (NMN) and pyrophosphate (PPi) (Abstract). Thus, the known reaction catalyzed by NAMPT utilizes PRPP as a substrate for formation of NMN rather than phosphoric acid. Hove-Jensen et al. (Microbiology and Molecular Biology Reviews, 2017, Vol. 81, Issue 1, PTO-892) further teach that PRPP is synthesized from ribose-5-phosphate (R5P) and ATP by PRPP synthase, resulting in formation of PRPP and AMP. Hove-Jensen et al. explain that PRPP constitutes an activated form of ribose-5-phosphate and provides the ribosyl moiety in phosphoribosyl-transfer reactions (Abstract; page 3, para. 4). Accordingly, the state of prior art teaches a biochemical pathway in which R5P is converted to PRPP using ATP and PRPP thereafter serves as a substrate, together with nicotinamide, for NAMPT-catalyzed formation of NMN. In contrast, claim 1 recites in step 3 adding phosphoric acid to the buffer containing dissolved nicotinamide and ribose to conduct an “activated phosphorylation reaction”, followed in step 4 by adding NMN synthetase to promote “the reaction of nicotinamide and phosphoric acid to generate NMN”. The specification does not explain how the recited phosphoric acid, nicotinamide, ribose, and R5P provide the PRPP substrate required by the known NAMPT reaction, nor does the specification describe an alternative biochemical pathway by which NMN synthetase catalyzes a reaction of nicotinamide and phosphoric acid to generate NMN. The quantity of experimentation necessary: One of ordinary skill in the art would need to determine what reaction occurs during the “activated phosphorylation reaction” of step 3, what product or intermediate is generated by that reaction, whether PRPP or another activated ribose-phosphate substrate is required for the subsequent NMN-forming reaction, how such a substrate is generated from the materials recited in the claim, what substrates are actually acted upon by the NMN synthetase in step 4, and how phosphoric acid participates in the formation of NMN. Such experimentation would extend beyond routine optimization of known reaction parameters, such as temperature, pH, reaction time, or enzyme concentration, because the skilled artisan would first need to determine an operative biochemical pathway and the necessary substrates and intermediates for carrying out the claimed reaction. Accordingly, the quantity and nature of experimentation required weighs against enablement. The predictability or unpredictability of the art: The claimed subject matter involves an enzyme-catalyzed biochemical reaction in which enzyme activity depends upon substrate recognition and reaction specificity. The state of art establishes that NAMPT/NMN synthetase catalyzes formation of NMN using nicotinamide and PRPP as substrates. The known ability of NAMPT to catalyze that reaction would not establish that the enzyme would also catalyze the materially different reaction recited in claim 1 between nicotinamide and phosphoric acid. The specification does not provide evidence or technical explanation demonstrating that phosphoric acid can substitute for PRPP or otherwise participate in an NMN synthetase-catalyzed formation of NMN. Accordingly, one of ordinary skill in the art could not reasonably predict that the recited reaction would successfully generate NMN based on the specification and knowledge in the art. Genentech, 108 F.3d at 1366, states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion.” And “patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable.” Therefore, in view of the Wands factors, as discussed above, particularly the state of art and the lack of guidance or working examples, Applicant fails to provide information sufficient to practice the claimed invention. Claims 2 – 6 and 11 – 13 are rejected for the same reasons set forth above with respect to claim 1 because the claims depend from claim 1 and therefore incorporate the limitations of steps 3 – 4. The additional limitations recited in the dependent claims do not provide the missing technical teaching as to what reaction occurs during the “activated phosphorylation reaction” of step 3 or how NMN synthetase catalyzes the recited reaction of nicotinamide and phosphoric acid to generate NMN in step 4. Conclusion No claim is found to be allowable. THIS ACTION IS MADE NON-FINAL. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HOI YAN LEE whose telephone number is 571-270-0265. The examiner can normally be reached Monday - Thursday 7:30 - 17:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, SCARLETT GOON can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /H.Y.L./Examiner, Art Unit 1693 /JONATHAN S LAU/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Oct 09, 2023
Application Filed
Mar 31, 2026
Non-Final Rejection mailed — §112
Jun 08, 2026
Response Filed
Sep 11, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747260
SYNTHESIS OF OLIGOMERIC COMPOUNDS COMPRISING PHOSPHOROTHIOATE DIESTER AND PHOSPHODIESTER LINKAGES
4y 10m to grant Granted Sep 29, 2026
Patent 12653805
TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY
4y 10m to grant Granted Jun 16, 2026
Patent 12599591
Vemurafenib and salts thereof for use in the treatment of enteroviral infections
5y 0m to grant Granted Apr 14, 2026
Patent 12577227
WDR5 INHIBITORS AND MODULATORS
4y 3m to grant Granted Mar 17, 2026
Patent 12570684
DPAGT1 INHIBITORS OF CAPURAMYCIN ANALOGUES AND THEIR ANTIMIGRATORY ACTIVITIES OF SOLID TUMORS
3y 2m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
38%
Grant Probability
99%
With Interview (+76.6%)
3y 5m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 89 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month